Evercore ISI cuts Kenvue stock price target to $18 on FDA acetaminophen review

Evercore ISI lowered its price target on Kenvue Inc (KVUE) to $18.00 from $23.00, maintaining an "In Line" rating, citing potential headline and reputational risks following an FDA announcement to review the safety label for acetaminophen, the active ingredient in Kenvue's Tylenol, due to suggested links with neurological conditions. This downgrade, reflecting concerns over consumer behavior shifts rather than litigation, comes as KVUE shares trade near 52-week lows, highlighting growing investor scrutiny despite some analyst counterparts maintaining higher price targets and downplaying legal risks.

Analysis

Kenvue Inc. (KVUE) is facing significant headwinds as regulatory scrutiny intensifies around its cornerstone Tylenol brand. Evercore ISI has responded by cutting its price target to $18.00 from $23.00, citing headline and reputational risks stemming from an FDA announcement to review the safety label of acetaminophen. The stock is reflecting this pressure, trading near its 52-week low after a decline of over 25% in the last six months. Evercore's revised valuation model, which yields a price target at the midpoint of low-to-medium scenarios, explicitly focuses on potential shifts in consumer behavior rather than immediate litigation risk. This cautious stance contrasts with other analysts, creating a wide valuation gap; JPMorgan maintains an Overweight rating with a $24.00 target, deeming the claims speculative, while Canaccord Genuity holds a Buy with a $26.00 target, expressing confidence in minimal legal repercussions. This divergence highlights the market's uncertainty in quantifying the financial impact of the potential label change on Kenvue's largest product line.

Key Decisions for Investors

• Investors should closely monitor all communications from the FDA and the Department of Health and Human Services regarding the acetaminophen safety review, as this is the primary catalyst for KVUE's stock performance.
• Given the stock is trading near 52-week lows and below even the most bearish analyst target, a significant degree of negative sentiment appears priced in, presenting a potential value opportunity if regulatory fears are not fully realized.
• The wide dispersion in analyst price targets ($18 to $26) underscores a high level of uncertainty; it may be prudent to consider positioning based on one's tolerance for regulatory risk and view the current situation as a test of brand resilience and consumer loyalty.